ClinicalTrials.gg
Not yet recruitingNCT07132398STARGlu-NMOUpdated Aug 20, 2025

Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD

A Phase 3 interventional study of Slow-tapering glucocorticoids + Inebilizumab and Rapid-tapering glucocorticoids + Inebilizumab in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorders (NMOSD), sponsored by Tianjin Medical University General Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-20.

Sponsored by Tianjin Medical University General Hospital · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Neuromyelitis Optica by Tianjin Medical University General Hospital — 5 open to participants now, 8 under way, 3 of them phase 3. Neuromyelitis Optica · Tianjin Medical University General Hospital.

Planned enrollment
2nd of 14
170 · median 24
Started
2025
with 3 others
Phase 3
2 of 15
2 open now
Registered
13th of 15
by date

Among the 15 studies in Neuromyelitis Optica by Tianjin Medical University General Hospital, this one is the 2nd largest by planned enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2025, is one of 2 in phase 3, and was the 13th registered.

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

Browse Neuromyelitis Optica studies →

Open to participants now

5 of the 15 studies in Neuromyelitis Optica by Tianjin Medical University General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 50 Neuromyelitis Optica studies recruiting now, 29 (58%) set no upper age limit and 16 (32%) stop at 75 or younger; 11 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Neuromyelitis Optica by Tianjin Medical University General Hospital, or all of them as a file.
02

Study summary

Neuromyelitis optica spectrum disorder (NMOSD) is a central nervous system autoimmune condition mainly involving the spinal cord, optic nerves, and area postrema. The anti-aquaporin-4 (AQP4)-Immunoglobulin G (IgG) is a specific biomarker for NMOSD. Glucocorticoids(GCs) are used as first-line treatment for NMOSD. Oral glucocorticoids tapering is always suggested following the pused therapy in the maintenance phase. Inebilizumab, a humanized monoclonal antibody targeting CD19, has been proven effective in preventing NMOSD relapses. This study aims to evaluate and compare the efficacy and differences between glucocorticoids slow-tapering and rapid-tapering strategies combined with inebilizumab in preventing relapses in AQP4-IgG-seropositive NMOSD patients following an acute attack, with the goal of determining the optimal approach to steroid tapering and discontinuation after initiation of inebilizumab.

03

Conditions studied

  • Neuromyelitis Optica (NMO)
  • Neuromyelitis Optica Spectrum Disorders (NMOSD)

Browse trials for

Keywords

  • NMO
  • NMOSD
  • Inebilizumab
  • Glucocorticoids
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability and willingness to provide written and comply with the requirements of the study protocol.
  2. Age ≥18 years, regardless of sex.
  3. Diagnosis of NMOSD according to the 2015 International Panel for NMO Diagnosis (IPND) criteria.
  4. Serum AQP4-IgG antibody positivity at screening.
  5. An acute clinical attack (including the first attack) within 1 month before screening. After the acute attack was treated with high-dose , the current oral prednisone dose was reduced to 60 mg per day.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding women, or women planning to become pregnant during the study period.
  2. Subjects with any serious acute, chronic, or recurrent infections (e.g., pneumonia, pyelonephritis, recurrent pneumonia, chronic bronchiectasis, tuberculosis, etc.).
  3. Carriers of virus, or patients with chronic active hepatitis B or C, other chronic liver diseases, or infection.
  4. Abnormal liver function (/AST >2 times the ); moderate to severe renal impairment ( \<60 mL/min/1.73 m²).
  5. Active .
  6. Severe immunodeficiency.
  7. Receipt of any B-cell depleting therapy within 6 months prior to initiation of baseline treatment, with B-cell counts below the lower limit of normal.
  8. Receipt of other treatments within 30 days prior to initiation of baseline treatment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Active comparator
    Slow-tapering glucocorticoids + Inebilizumab arm

    Drug: Slow-tapering glucocorticoids + Inebilizumab

  • Active comparator
    Rapid-tapering glucocorticoids + Inebilizumab arm

    Drug: Rapid-tapering glucocorticoids + Inebilizumab

Interventions

  • DrugSlow-tapering glucocorticoids + Inebilizumab

    Slow-tapering glucocorticoids+Inebilizumab arm: A 300 mg intravenous infusion of inebilizumab will be administered on Day 1 and Day 15, followed by 300 mg infusions every 26 weeks thereafter. Prednisone will be initiated at a daily dose of 60 mg as concomitant therapy with inebilizumab. The prednisone dose will be tapered as follows: a reduction of 5 mg every 2 weeks until reaching 20 mg/day(Week 16); thereafter, a reduction of 5 mg every 4 weeks until discontinuation (a total duration of 32 weeks for combined inebilizumab and glucocorticoids therapy).

  • DrugRapid-tapering glucocorticoids + Inebilizumab

    Rapid-tapering glucocorticoids+Inebilizumab arm: A 300 mg intravenous infusion of inebilizumab will be administered on Day 1 and Day 15, followed by 300 mg infusions every 26 weeks thereafter. Prednisone will be initiated at a daily dose of 60 mg as concomitant therapy with inebilizumab, with a tapering schedule of 5 mg reduction per week until discontinuation (a total duration of 12 weeks for combined inebilizumab and glucocorticoids therapy).

06

What researchers measure

Primary outcomes

  1. First adjudicated relapse event within 54 weeks

    Time frame: Baseline, 54 Weeks

Secondary outcomes

  1. Change in Expanded Disability Status Scale (EDSS) score from baseline at 54 weeks

    Time frame: Baseline, 54 Weeks

  2. Change in Low-contrast Visual Acuity (LCVA) from baseline at 54 weeks

    Time frame: Baseline, 54 Weeks

  3. Change in Timed 25-Foot Walk (T25-FW) test from baseline at 54 weeks

    Time frame: Baseline, 54 Weeks

  4. Change in Expanded Disability Status Scale (EDSS) score from baseline at 106 weeks

    Time frame: Baseline, 106 Weeks

  5. Change in Low-contrast Visual Acuity (LCVA) from baseline at 106 weeks

    Time frame: Baseline, 106 Weeks

  6. Change in Timed 25-Foot Walk (T25-FW) test from baseline at 106 weeks

    Time frame: Baseline, 106 Weeks

  7. Change in serum Neurofilament Light chain (sNfL) levels at 54 weeks

    Time frame: Baseline, 54 Weeks

  8. Change in serum Glial Fibrillary Acidic Protein (sGFAP) levels at 54 weeks

    Time frame: Baseline, 54 Weeks

  9. Change in serum AQP4-IgG titer at 54 weeks

    Time frame: Baseline, 54 Weeks

  10. Change in serum Neurofilament Light chain (sNfL) levels at 106 weeks

    Time frame: Baseline, 106 Weeks

  11. Change in serum Glial Fibrillary Acidic Protein (sGFAP) levels at 106 weeks

    Time frame: Baseline, 106 Weeks

  12. Change in serum AQP4-IgG titer at 106 weeks

    Time frame: Baseline, 106 Weeks

  13. Change in Visual Analogue Scale (VAS) score from baseline at 54 weeks

    Time frame: Baseline, 54 Weeks

  14. Change in Visual Analogue Scale (VAS) score from baseline at 106 weeks

    Time frame: Baseline, 106 Weeks

  15. Change in Quality of Life (QoL) score from baseline at 54 weeks

    Time frame: Baseline, 54 Weeks

  16. Change in Quality of Life (QoL) score from baseline at 106 weeks

    Time frame: Baseline, 106 Weeks

  17. Proportion of Relapse-free Participants at 54 weeks

    Time frame: Baseline, 54 Weeks

  18. Proportion of Relapse-free Participants at 106 weeks

    Time frame: Baseline, 106 Weeks

  19. Percentage of patients in glucocorticoid-free remission between 54 and 106 weeks

    Time frame: 54 Weeks, 106 Weeks

  20. Annualized Relapse Rate (ARR) at 54 weeks

    Time frame: Baseline, 54 Weeks

  21. Annualized Relapse Rate (ARR) at 106 weeks

    Time frame: Baseline, 106 Weeks

  22. Daily and acumulate dose of glucocorticoids at relapse before 54 weeks

    Time frame: Baseline, 54 Weeks

  23. Adverse events (AEs) and Serious AEs (SAEs) at 54 weeks

    Time frame: Baseline, 54 Weeks

  24. Immunoglobulin levels at 54 weeks

    Time frame: Baseline, 54 Weeks

  25. Pelvic X-ray at 54 weeks

    Time frame: Baseline, 54 Weeks

  26. Adverse events (AEs) and Serious AEs (SAEs) at 106 weeks

    Time frame: Baseline, 106 Weeks

  27. Immunoglobulin levels at 106 weeks

    Time frame: Baseline, 106 Weeks

  28. Pelvic X-ray at 106 weeks

    Time frame: Baseline, 106 Weeks

Other outcomes

  1. Lymphocyte Subpopulation Monitoring at 54 weeks

    Time frame: Baseline, 54 Weeks

  2. Lymphocyte Subpopulation Monitoring at 106 weeks

    Time frame: Baseline, 106 Weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Aug 2027, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2025
First posted
Aug 20, 2025
StartEst.
Sep 1, 2025
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2028
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07132398
Lead sponsor
Tianjin Medical University General Hospital
Responsible party
Chun-Sheng Yang (Clinical Professor, Tianjin Medical University General Hospital) — Principal investigator
First posted
Aug 20, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Aug 20, 2025

Study contacts

Chun-Sheng Yang, M.D., Ph.D.
Contact
cyang01@tmu.edu.cn
+86-022-60814587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion